

Exhibit 3

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS
USA, INC., and AKORN INC.,
Petitioners

v.

ALLERGAN, INC.
Patent Owner

Case IPR2016-01127¹
Patent 8,685,930

**PATENT OWNER'S UPDATED MANDATORY NOTICES PURSUANT TO
37 C.F.R. § 42.8(a)(3)**

¹ Cases IPR2017-00576 and IPR2017-00594 have been joined with this proceeding.

EXHIBIT LIST

Exhibit No.	Description
EX. 2001	NDA 21-023 Cyclosporine Ophthalmic Emulsion 0.05%, Original NDA Filing, Vol. 1 (Feb. 24, 1999)
EX. 2002	U.S. Pat. No. 4,839,342
EX. 2003	Said et al., Investigative Ophthalmology & Visual Science, vol. 48, No. 11 (Nov. 2007):5000-5006
EX. 2004	Alba et al., Folia Ophthalmol. Jpn. 40:902-908 (1989)
EX. 2005	Stedman's Medical Dictionary, definition of therapeutic
EX. 2006	Dorland's Illustrated Medical Dictionary, definition of therapeutic
EX. 2007	Stedman's Medical Dictionary, definition of palliative
EX. 2008	RESTASIS® label
EX. 2009	Murphy, R., "The Once and Future Treatment of Dry Eye," Review of Optometry, pp. 73-75 (Feb. 15, 2000)
EX. 2010	RESERVED
EX. 2011	Agarwal, Priyanka and Ilva D. Rupenthal, "Modern Approaches to the Ocular Delivery of Cyclosporine A," Drug Discovery Today, vol. 21, no. 6 (June 2016)
EX. 2012	Damato et al., "Senile Atrophy of the Human Lacrimal Gland: The Contribution of Chronic Inflammatory Disease," British Journal of Ophthalmology (1984)
EX. 2013	Higuchi, "Physical Chemical Analysis of Percutaneous Absorption Process From Creams and Ointments," Seminar, New York City (1959)
EX. 2014	Lallemand et al., "Cyclosporine a Delivery to the Eye: A Pharmaceutical Challenge," European Journal of Pharmaceutics and Biopharmaceutics (2003)

EX. 2015	das Neves et al., “Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies,” Springer Science (2014)
EX. 2016	Power et al., “Effect of Topical Cyclosporin A on Conjunctival T Cells in Patients with Secondary Sjögren’s Syndrome,” Cornea 12(6): 507-511 (1993)
EX. 2017	Schaefer et al., “Skin Permeability,” Springer-Verlag (1982)
EX. 2018	Stern et al., “The Pathology of Dry Eye: The Interaction Between the Ocular Surface and Lacrimal Glands,” Cornea 17(6): 584-589 (1998)
EX. 2019	Wepierre, Jacques and Jean-Paul Marty, “Percutaneous Absorption of Drugs,” Elsevier/North-Holland Biomedical Press (1970)
EX. 2020	Williamson et al., “Histology of the Lacrimal Gland in Keratoconjunctivitis Sicca,” Brit. F. Ophthal /91973)
EX. 2021	“Approved Drug Products with Therapeutic Equivalence Evaluations,” U.S. Department of Health and Human Services, 37 th Edition (2017)
EX. 2022	Lemp, Michael A., “Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,” CLAO Journal, vol. 21, no. 4 (October 1995)
EX. 2023	Deposition transcript of Mansoor Amiji, Ph.D
EX. 2024	Declaration of John D. Sheppard, M.D., M.M.Sc.
EX. 2025	Declaration of Dr. Thorsteinn Loftsson, Ph.D.
EX. 2026	Declaration of Eric Robinson
EX. 2027	Allergan PK-98-074 Report
EX. 2028	Declaration of Robert S. Maness, Ph.D.
EX. 2029	DiMasi, “Risks in New Drug Development: Approval Success Rates for Investigational Drugs,” Clinical Pharmacology and Therapeutics, May 2001
EX. 2030	FDA Review, “The Drug Development and Approval Process”

EX. 2031	Allergan – NYSE: AGN – Company Profile
EX. 2032	Drugs@FDA: FDA Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021023
EX. 2033	Drugs@FDA: FDA Approved Drug Products, Restasis Approved, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis_Approv.PDF
EX. 2034	Drugs@FDA: FDA Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050790
EX. 2035	Facts About Dry Eye, https://nei.nih.gov/health/dryeye/dryeye
EX. 2036	Christopher Glenn, “New Thinking Spurs New Products,” Review of Ophthalmology, February 15, 2003
EX. 2037	Mark B. Abelson, MD and Jason Casavant, “Give Dry Eye a One-two Punch,” Review of Ophthalmology, March 15, 2003
EX. 2038	Deposition of David LeCause, February 17, 2017
EX. 2039	Joan-Marie Stiglich ELS, “Restasis: the road to approval,” Ocular Surgery News, March 1, 2003
EX. 2040	Lynda Charters, “Increased Tear Production,” Ophthalmology Times, February 1, 2003
EX. 2041	RESERVED
EX. 2042	Jonathan R. Pirnazar, MD, “Taking a Custom Approach to Dry Eye Treatment,” Ophthalmology Management, February 1, 2004
EX. 2043	RESERVED
EX. 2044	FDA label for Xiidra®
EX. 2045	RESERVED
EX. 2046	Restasis Strategic Plan Forecast 2009-2013

Case No.: IPR2016-01127
Attorney Docket No.: 13351-0008IP1

EX. 2047	Allergan Inc., Credit Suisse First Boston Equity Research Report, Jan 30, 2003
EX. 2048	Allergan Inc., Buckingham Research Group Equity Research Report, Feb 5, 2003
EX. 2049	Allergan Inc., SalomonSmithBarney Equity Research Report, Feb 12, 2003
EX. 2050	Allergan Inc., Morgan Stanley Equity Research Report, Jan 30, 2003
EX. 2051	Restasis P&L (US Only excl. Canada and Puerto Rico)
EX. 2052	Allergan Inc., Morgan Stanley Equity Research Report, Apr 30, 2004
EX. 2053	Allergan Inc., JP Morgan Equity Research Report, Nov 1, 2005
EX. 2054	RESERVED
EX. 2055	“commercial Restasis Formulary June 2006.xls”
EX. 2056	“NOVEMBER 2006 input MHC Report Restasis Playbook data.ppt”
EX. 2057	Restasis® 2013 Managed Markets Tactics & Preliminary Budget, August 8, 2012
EX. 2058	RESERVED
EX. 2059	RESERVED
EX. 2060	“Allergan Inc. (AGN) - Q4 2002 Financial Release Conference Call Wednesday, January 29, 2003 11:00 am” Fair Disclosure Financial Network
EX. 2061	Restasis Launch Marketing Plan, dated February 12-13, 2003
EX. 2062	Allergan Dry Eye, “Dry Eye Franchise 2014 Business Plan,” 2014 U.S. Eye Care Sales & Marketing Plan, September 9, 2013
EX. 2063	Allergan Eye Care, “US Dry Eye Strat Plan Narrative: Summary Version,” April 16, 2011
EX. 2064	Kline, Kate, “Restasis Professional Critical Issues,” Allergan Dry Eye, 2010

EX. 2065	Allergan Dry Eye, “Restasis Business Update,” August 16, 2010
EX. 2066	“Sales-Units_2011-2016_AllData_NSP_Feb-19-2017_RESTASIS.xlsx”
EX. 2067	RESERVED
EX. 2068	Iazuka and Jin, “The Effect of Prescription Drug Advertising on Doctor Visits,” Journal of Economics and Management Strategy, 2007
EX. 2069	Bradford, Kleit, Nietert, et al, “How Direct-to-Consumer Television Advertising for Osteoarthritis Drugs Affect Physicians’ Prescribing Behavior,” Health Affairs, 2006
EX. 2070	Calfee, Winston, and Stempski, “Direct-to-Consumer Advertising and the Demand for Cholesterol Reducing Drugs,” Journal of Law and Economics, 2002
EX. 2071	Bradford, Kleit, Nietert, et al, “Effects of Direct-to-Consumer Advertising of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on Attainment of LDL-C Goals,” Clinical Therapeutics, 2006
EX. 2072	Restasis NPA Monthly
EX. 2073	Restasis Projects, Global R&D Cost
EX. 2074	Refresh Endura Lubricant Eye Drops (Allergan), Theodora
EX. 2075	Declaration of Jonathan Singer in support of Petitioner’s Motion for <i>Pro Hac Vice</i> Admission
EX. 2076	Memorandum Opinion and Order, <i>Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., et al.</i> , Case No. 2:15-cv-1455-WCB
EX. 2077	Nussenblatt, R. et al. <i>Local Cyclosporine Therapy for Experimental Autoimmune Uveitis in Rats</i> . Arch Ophthalmology, Volume 103, October 1985.
EX. 2078	Medical Officer’s Review of NDA 21-023

Case No.: IPR2016-01127
Attorney Docket No.: 13351-0008IP1

EX. 2079	Correction to Sall article (Ex. 1007), Ophthalmology, Vol. 107, No. 7, July 2000.
EX. 2080	GraphPad Calculation of Bloch Table 2 – 3 mo. B vs A.
EX. 2081	GraphPad Calculation of Bloch Table 2 – 3 mo. C vs A.
EX. 2082	Deposition transcript of Andrew F. Calman, M.D., Ph.D.
EX. 2083	Deposition transcript of Daniel A. Bloch, Ph.D.
EX. 2084	Deposition transcript of Ivan T. Hofmann
EX. 2085	Assignment

Under 37 C.F.R. § 42.8(a)(3), Patent Owner Saint Regis Mohawk Tribe and Allergan, Inc. hereby submit the following mandatory change-of-information notice in connection with consolidated cases listed in the caption above.

A. Real Party-In-Interest – 37 CFR § 42.8(b)(1)

Saint Regis Mohawk Tribe (the “Tribe”) hereby makes a special appearance² before this Board to respectfully request that the Board immediately enter an order staying all proceedings in this and all related IPRs set forth on the cover page of this Motion pending resolution of its motion to dismiss based on sovereign immunity. The Tribe has taken assignment of all six patents involved in this consolidated proceeding. EX. 2085 (Assignment). The Tribe does not consent to this proceeding.

B. Related Matters – 37 C.F.R. § 42.8(b)(2)

Unchanged.

C. Lead and Back-up Counsel – 37 C.F.R. § 42.8(b)(3)

Allergan is exclusively represented in this proceeding by the following Lead and Back-Up Counsel:

² See *Friends of Amador County v. Salazar*, 554 Fed.Appx. 562, 564 (9th Cir. 2014) (tribe made special appearance before district court so as not to waive immunity to present Rule 19 motion); *Saginaw Chippewa Indian Tribe of Michigan v. NLRB*, 838 F.Supp.2d 598, 601 (E.D. Mich. 2011)(tribe made special appearance before NLRB to challenge jurisdiction on immunity grounds).

Case No.: IPR2016-01127
Attorney Docket No.: 13351-0008IP1

LEAD COUNSEL	BACK-UP COUNSEL
<p>Dorothy P. Whelan, Reg. No. 33,814 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2509 Email: IPR13351-0008IP1@fr.com Fax: (612) 288-9696</p>	<p>Michael Kane, Reg. No. 39,722 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (612) 337-2502 Email: PTABInbound@fr.com Fax: (612) 288-9696</p> <p>Susan Morrison Colletti, Reg. No. 56,332 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (302) 778-8434 Email: PTABInbound@fr.com Fax: (612) 288-9696</p> <p>Robert M. Oakes, Reg. No. 62,189 3200 RBC Plaza 60 South Sixth Street Minneapolis, MN 55402 Tel: (302) 778-8477 Email: PTABInbound@fr.com Fax: (612) 288-9696</p>

Case No.: IPR2016-01127
Attorney Docket No.: 13351-0008IP1

The Tribe is exclusively represented in this proceeding by the following Back-Up Counsel:

BACK-UP COUNSEL
Alfonso Chan, Reg. No. 45,964 Shore Chan DePumpo LLP 901 Main Street, Suite 3300 Dallas, TX 75201 Telephone: (214) 593-9110 Email: achan@shorechan.com Fax: (214) 593-9111
Joseph DePumpo, Reg. No. 38,124 Shore Chan DePumpo LLP 901 Main Street, Suite 3300 Dallas, TX 75201 Telephone: (214) 593-9110 Email: jdepumpo@shorechan.com Fax: (214) 593-9111

D. Electronic Service

Please address all correspondence and service to counsel as listed above.

Allergan consents to service by email at IPR13351-0008IP1@fr.com (ref.: Docket No. IPR13351-0008IP1). The Tribe consents to service by email at IPR01227@shorechan.com.

Dated: September 8, 2017

Respectfully submitted,

/Michael Kane/

Michael Kane
Reg. No. 39,722

Customer Number 26191
Fish & Richardson P.C.
Telephone: (612) 337-2502
Facsimile: (612) 288-9696

CERTIFICATE OF SERVICE

Pursuant to 37 CFR §§ 42.6(e)(4) and 42.205(b), the undersigned certifies that on September 8, 2017, a complete and entire copy of this Patent Owner Allergan, Inc.'s Updated Mandatory Notices, Power of Attorney, and supporting exhibit were provided via electronic service, to the Petitioner by serving the correspondence address of record as follows:

Steven W. Parmelee
Michael T. Rosato
Jad A. Mills
Wendy L. Devine
Douglas H. Carsten
Wilson Sonsini Goodrich & Rosati
701 Fifth Avenue, Suite 5100
Seattle, WA 98104-7036
sparmelee@wsgr.com
mrosato@wsgr.com
jmills@wsgr.com
wdevine@wsgr.com
dcarsten@wsgr.com

Case No.: IPR2016-01127
Attorney Docket No.: 13351-0008IP1

Michael R. Dzwonczyk
Azy S. Kokabi
Travis B. Ribar
Shelia Blackston
Sughrue Mion, PLLC
2100 Pennsylvania Ave., NW, Suite 800
Washington, DC 20037
mdzwonczyk@sughrue.com
akokabi@sughrue.com
tribar@sughrue.com
sblackston@sughrue.com

Gary J. Speier
Mark D. Schuman
Carlson, Caspers, Vandenburg, Lindquist & Schuman, P.A.
225 South Sixth Street, Suite 4200
Minneapolis, Minnesota 55402
gspeier@carlsoncaspers.com
mschuman@carlsoncaspers.com
IPRCyclosporine@carlsoncaspers.com

/Jessica K. Detko/
Jessica K. Detko
Fish & Richardson P.C.
60 South Sixth Street, Suite 3200
Minneapolis, MN 55402
(612) 337-2516

**UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD**

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC., and AKORN INC.,¹
Petitioners,

v.

ALLERGAN, INC.,
Patent Owner.

Case IPR2016-01127 (8,685,930 B2)
Case IPR2016-01128 (8,629,111 B2)
Case IPR2016-01129 (8,642,556 B2)
Case IPR2016-01130 (8,633,162 B2)
Case IPR2016-01131 (8,648,048 B2)
Case IPR2016-01132 (9,248,191 B2)

**PATENT OWNER SAINT REGIS MOHAWK TRIBE'S
POWER OF ATTORNEY**

¹ Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017- 00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017- 00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Under 37 C.F.R. § 42.10(b), Patent Owner Saint Regis Mohawk Tribe hereby appoints the following practitioners as its attorneys to prosecute its special appearance in this *Inter Partes* Review and to transact all business in the Patent and Trademark Office connected therewith:

Alfonso Chan, Reg. No. 45,964
Shore Chan DePumpo LLP
901 Main Street, Suite 3300
Dallas, TX 75201
Telephone: (214) 593-9110
Email: achan@shorechan.com
Fax: (214) 593-9111

Joseph DePumpo, Reg. No. 38,124
Shore Chan DePumpo LLP
901 Main Street, Suite 3300
Dallas, TX 75201
Telephone: (214) 593-9110
Email: jdepumpo@shorechan.com
Fax: (214) 593-9111

I have the authority to execute this document on behalf of Saint Regis Mohawk Tribe

By:  _____

Name: Dale White

Title: General Counsel

Date: September 8, 2017

EXECUTION VERSION

SHORT FORM PATENT ASSIGNMENT

This Patent Assignment (this "**Assignment**") is made as of September 8, 2017 (such date, the "**Effective Date**"), by and between Allergan, Inc., a Delaware corporation ("**Assignor**"), and Saint Regis Mohawk Tribe, a federally-recognized sovereign Native American Tribe ("**Assignee**").

WHEREAS, Assignor owns the patents and patent applications set forth in Attachment A (the "**Patents**");

WHEREAS, Assignor desires to assign, transfer, convey and deliver to Assignee, and Assignee wishes to acquire from Assignor, all of its right, title and interest in, to and under the Patents; and

WHEREAS, pursuant to, and upon the terms, obligations and conditions of, the Patent Assignment Agreement dated as of September 8, 2017 (the "**Long Form Agreement**"), by and between Assignor and Assignee, Assignor desires to confirm and perfect its assignment, transfer, conveyance and delivery to Assignee of all of its right, title and interest in, to and under the Patents and in, to and under the inventions represented thereby, and Assignee is desirous of confirming and perfecting the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Assignment. As of the Effective Date, Assignor hereby conveys, transfers, assigns and delivers to Assignee, and Assignee hereby accepts the from Assignor, all of Assignor's right, title and interest in, to and under the Patents, together with any reissues, reexamination, divisions, continuations, continuations-in-part, extensions, and renewals of such Assigned Patents already granted and which may be granted thereon. The assignment contemplated herein is meant to be an absolute assignment and not by way of security.
2. Further Assurances. As may be necessary, Assignor shall execute, acknowledge and deliver such other instruments, documents and agreements and shall do such other things as may be reasonably necessary, proper or advisable to carry out its obligations under this Agreement and as may be reasonably necessary, proper or advisable to more completely effectuate, consummate, record, perfect or confirm the transactions contemplated hereby.
3. Recordation. The Assignor hereby authorizes the Director of Patents and Trademarks in the United States Patent and Trademark Office to record Assignee as the assignee and owner of the Assigned Patents and to deliver to Assignee, and to Assignee's attorneys, agents, successors or assigns, all official documents and communications as may be warranted by this Assignment, including but not limited to issuing any and all Letters Patents of the United States on inventions claimed in the Patents.
4. No Other Waivers of Sovereign Immunity. Assignee represents that it has not and will not waive its sovereign immunity or the sovereign immunity of any company, corporation, enterprise, authority, division, subdivision, branch or other agency, instrumentality or other government component of Assignee (each of the foregoing,

9-8-17
[Handwritten signatures and initials]

including Assignee, a "**Tribal Party**"), in each case, in relation to any inter partes review or any other proceeding in the United States Patent & Trademark Office or any administrative proceeding that may be filed for the purpose of invalidating or rendering unenforceable any Assigned Patents. For purposes of this Assignment Agreement, no provision of this Assignment Agreement should be interpreted to constitute a waiver of Assignee's or any other Tribal Party's sovereign immunity as to any inter partes review or similar proceedings.

5. General Provisions. Assignor and Assignee each acknowledge and agree that the representations, warranties, covenants, obligations and other terms contained in the Long Form Agreement shall not be superseded hereby, but shall remain in full force and effect to the full extent provided therein. To the extent that any provision of this Assignment is inconsistent or conflicts with the Long Form Agreement, the provisions of the Long Form Agreement shall control. The parties may execute this Assignment in multiple counterparts, any one of which need not contain the signature of more than one party, but all such counterparts taken together shall constitute one and the same instrument. Any counterpart may be executed by facsimile or PDF signature and such facsimile or PDF signature shall be deemed an original. The terms and conditions of this Assignment shall be binding upon the parties hereto and their respective successors and assigns. This Assignment shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.

[Signatures Appear On The Following Page]

9-8-17
AC ET m
AKB
9/8/17


IN WITNESS THEREOF, Assignor and Assignee have caused their respective duly authorized officers to execute this Assignment as of the Effective Date.

Saint Regis Mohawk Tribe

By: 

Name: Eric Thompson

Title: Tribal Chief

By: 

Name: Beverly Cook

Title: Tribal Chief

By: 

Name: Michael Connors

Title: Tribal Chief

Allergan, Inc.


By: 

Name: A. Robert D. Bailey

Title: President

Signature Page to Short Form Patent Assignment Agreement

9-8-17



9/8/17

Attachment A – The Patents

COUNTRY	PATENT NO.	ISSUE DATE	SERIAL NO.	FILING DATE	STATUS / COMMENTS
US	5,474,979	12-Dec-1995	08/243,279	17-May-1994	
US	5,981,607	9-Nov-1999	09/008,924	20-Jan-1998	
US	6,479,458	12-Nov-2002	10/005,829	8-Nov-2001	
US	8,629,111	14-Jan-2014	13/967,163	14-Aug-2013	
US	8,633,162	21-Jan-2014	13/967,179	14-Aug-2013	
US	8,642,556	4-Feb-2014	13/967,189	14-Aug-2013	
US	8,648,048	11-Feb-2014	13/967,168	14-Aug-2013	
US	8,685,930	01-Apr-2014	13/961,828	07-Aug-2013	
US	9,248,191	02-Feb-2016	14/222,478	21-Mar-2014	
US	-	-	13/961,835	07-Aug-2013	Abandoned
US	-	-	13/961,818	07-Aug-2013	Abandoned
US	-	-	13/961,808	07-Aug-2013	Abandoned
US	8,618,064	31-Dec-2013	11/897,177	28-Aug-2007	
US	-	-	15/585,320	3-May-2017	Pending
US	-	-	15/011,159	29-Jan-2016	Abandoned
US	-	-	60/503,137	15-Sep-2003	Lapsed Provisional
US	-	-	10/927,857	27-Aug-2004	Abandoned
US	7,135,455	14-Nov-2006	10/990,054	15-Nov-2004	
US	7,368,426	6-May-2008	11/429,050	5-May-2006	
US	-	-	11/998,505	30-Nov-2007	Abandoned
US	-	-	12/506,612	21-Jul-2009	Abandoned
US	7,151,085		10/990,055	15-Nov-2004	
US	7,902,155		11/479,741	30-Jun-2006	
US			11/479,481	30-Jun-2006	
US	-	-	11/181,509	13-Jul-2005	Abandoned
US	8,288,348	16-Oct-2012	11/917,448	13-Dec-2007	
US	-	-	13/649,287	11-Oct-2012	Abandoned
US	7,276,476	2-Oct-2007	11/181,187	13-Jul-2005	
US	-	-	11/181,409	13-Jul-2005	Abandoned
US	7,288,520	30-Oct-2007	11/255,821	19-Oct-2005	
US	8,563,518	22-Oct-2013	13/536,479	28-Jun-2012	
US	9,101,574	11-Aug-2015	11/181,409	13-Jul-2005	
US	-	-	14/822,682	10-Aug-2015	Pending
US	8,211,855	3-Jul-2012	11/857,223	18-Sep-2007	

Attachment A to Short Form Patent Assignment Agreement

9-8-17
 [Signature] 9/8/17
 [Signature] ET
 [Signature]

COUNTRY	PATENT NO.	ISSUE DATE	SERIAL NO.	FILING DATE	STATUS / COMMENTS
US	7,297,679	20-Nov-2007	11/181,178	13-Jul-2005	
US	8,575,108	5-Nov-2013	11/940,652	15-Nov-2007	
US	8,969,307	3-Mar-2015	14/071,427	4-Nov-2013	
US	-	-	14/635,648	2-Mar-2015	Pending
US	7,202,209	10-Apr-2007	11/181,428	13-Jul-2005	
US	8,536,134	17-Sep-2013	11/679,934	28-Feb-2007	
US	8,969,306	3-Mar-2015	14/027,006	13-Sep-2013	
US	-	-	14/635,734	2-Mar-2015	Pending
US	7,501,393	10-Mar-2009	11/161,218	27-Jul-2005	
US	8,906,861	9-Dec-2014	12/361,335	28-Jan-2009	
US	7,745,400	29-Jun-2010	11/548,631	11-Oct-2006	
US	-	-	13/966,744	14-Aug-2013	Abandoned
US	-	-	13/966,770	14-Aug-2013	Abandoned
US	-	-	13/966,849	14-Aug-2013	Abandoned
US	-	-	13/966,888	14-Aug-2013	Abandoned
US	-	-	13/966,925	14-Aug-2013	Abandoned
US	-	-	13/957,722	2-Aug-2013	Abandoned
US	-	-	13/957,772	2-Aug-2013	Abandoned
US	-	-	13/957,796	2-Aug-2013	Abandoned
US	-	-	13/957,858	2-Aug-2013	Pending
US	-	-	13/957,886	2-Aug-2013	Abandoned
US	8,501,174	6-Aug-2013	12/825,116	28-Jun-2010	
US	-	-	60/596,709	14-Oct-2005	Lapsed Provisional
US	7,557,082	7-Jul-2009	11/681,152	1-Mar-2007	
US	8,207,129	26-Jun-2012	12/497,886	6-Jul-2009	
US	-	-	60/779,120	3-Mar-2006	Lapsed Provisional
US	9,561,178	7-Feb-2017	11/781,095	20-Jul-2007	
US	-	-	11/858,200	20-Sep-2007	Abandoned
US	-	-	12/035,698	22-Feb-2008	Abandoned
US	-	-	15/425,836	6-Feb-2017	Pending
US	-	-	60/820,239	25-Jul-2006	Lapsed Provisional
US	-	-	60/829,796	17-Oct-2006	Lapsed Provisional
US	-	-	12/759,431	13-Apr-2010	Pending
US	-	-	14/491,907	19-Sep-2014	Abandoned
US	-	-	61/169,196	14-Apr-2009	Lapsed Provisional
US	-	-	12/771,952	30-Apr-2010	Abandoned
US	-	-	14/837,733	27-Aug-2015	Pending

Attachment A to Short Form Patent Assignment Agreement

COUNTRY	PATENT NO.	ISSUE DATE	SERIAL NO.	FILING DATE	STATUS / COMMENTS
US	-	-	61/174,824	1-May-2009	Lapsed Provisional
US	-	-	61/347,851	25-May-2010	Lapsed Provisional
US	-	-	13/115,764	25-May-2011	Abandoned
US	-	-	14/524,955	27-Oct-2014	Pending
US	-	-	13/969,468	16-Aug-2013	Abandoned
US	-	-	14/253,965	16-Apr-2014	Abandoned
US	-	-	15/051,155	23-Feb-2016	Pending
US	-	-	13/969,443	16-Aug-2013	Abandoned
US	-	-	14/253,137	15-Apr-2014	Abandoned
US	-	-	15/055,293	26-Feb-2016	Pending

Attachment A to Short Form Patent Assignment Agreement

9/8/17
9-8-17
me pc